Novartis hands Ophthotech a $1B deal for heavyweight wet AMD contender – FierceBiotech

Facebook
Novartis hands Ophthotech a $1B deal for heavyweight wet AMD contender
FierceBiotech
Novartis ($NVS) has scooped up the ex-U.S. rights to Ophthotech’s Fovista–its late-stage therapy for wet age-related macular degeneration that hopes to one day rival heavyweight franchises controlled by Roche ($RHHBY) and Regeneron ($REGN)–in a …
Ophthotech Corp (OPHT), Novartis Enter ex-US Licensing Agreement for Wet StreetInsider.com (subscription)
Ophthotech may get over $1 billion from eye drug deal with NovartisReuters
Novartis announces exclusive agreement to extend leadership in ophthalmology MarketWatch
The Wall Street TranscriptXconomy
all 22 news articles

…read more

Source: Wet Macular Degeneration News From Google News

Leave a Comment